BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Orpathys (Savolitinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Orpathys (Savolitinib)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05620628-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT05620628)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2.\nStudy: Ph2 Study of Savoliti
 nib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastri
 c Cancer(VIKTORY-2)\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/savolitinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05620628
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322890-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT04322890)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Treatment Strategies and Survival Outcome for Non-small Cell Lung 
 Cancer With Oncogenic Mutation\nEstimated primary completion: 24 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0432289
 0
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322783-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT07322783)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Combined With Savolitinib in the Treatment of NSCLC Wi
 th Low Copy Number MET Amplification\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7322783
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374603-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT05374603)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Adva
 nced or Metastatic NSCLC\nEstimated primary completion: 18 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05374603
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05777278-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Orpathys (Savolitinib): Phase 1/2 readout est. (NCT05777278)
DESCRIPTION:Orpathys (Savolitinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wild
 type NSCLC With MET Overexpression\nEstimated primary completion: 31 Augus
 t 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05777
 278
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT06563999)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage II
 I NSCLC Harboring Rare Mutations.\nEstimated primary completion: 1 Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06563
 999
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT06692491)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2.\nStudy: Study of Precision Tr
 eatment for Rare Tumours in China Guided by PDO and NGS\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/savolitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06692491
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009836-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Orpathys (Savolitinib): Phase 3 readout est. (NCT05009836)
DESCRIPTION:Orpathys (Savolitinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+
 /MET+ Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 
 30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/savoliti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05009836
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683403-2032@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Orpathys (Savolitinib): Phase 1/2 readout est. (NCT07683403)
DESCRIPTION:Orpathys (Savolitinib)\, phase 1/2.\nStudy: Savolitinib Plus Ce
 tuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorect
 al Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/savolitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07683403
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
